

GLAXOSMITHKLINE PLC

Form 6-K

April 17, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 17 April 2018

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms E Walmsley  
 b) Position/status Chief Executive Officer

c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882

b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.

	Price(s)	Volume(s)
	£14.296	3,639.339
c) Price(s) and volume(s)	£14.296	5,897.033
	£14.296	7.046.678

d) Aggregated information  
 Aggregated volume Price 16,583.050  
 £14.296

e) Date of the transaction 2018-04-12  
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr R G Connor
  - b) Position/status President, Global Manufacturing & Supply
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882								
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.								
c) Price(s) and volume(s)	<table border="0" style="margin-left: 20px;"> <thead> <tr> <th style="text-align: left;">Price(s)</th> <th style="text-align: left;">Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£14.296</td> <td>2,125.159</td> </tr> <tr> <td>£14.296</td> <td>2,031.057</td> </tr> <tr> <td>£14.296</td> <td>2,793.963</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£14.296	2,125.159	£14.296	2,031.057	£14.296	2,793.963
Price(s)	Volume(s)								
£14.296	2,125.159								
£14.296	2,031.057								
£14.296	2,793.963								
d) Aggregated information	Aggregated volume Price								
	6,950.178 £14.296								
e) Date of the transaction	2018-04-12								
f) Place of the transaction	London Stock Exchange (XLON)								

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr L Debruyne
  - b) Position/status President, Global Vaccines
  - c) Initial notification/ amendment Initial notification

amendment

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.
 

Price(s)	Volume(s)
£14.296	534.931
- c) Price(s) and volume(s)
 

£14.296	1,523.594
£14.296	2,121.579

- d) Aggregated information
 

Aggregated volume	4,180.105
Price	£14.296

- e) Date of the transaction 2018-04-12
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr L Miels
  - b) Position/status President, Global Pharmaceuticals
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	£14.296	3,489.352
c) Price(s) and volume(s)	£14.296	2,410.334
	£14.296	3,628.919
d) Aggregated information	9,528.606	
d) Aggregated volume Price	£14.296	
e) Date of the transaction	2018-04-12	
f) Place of the transaction	London Stock Exchange (XLON)	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr S Dingemans
b) Position/status	Chief Financial Officer
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
--	--	--

	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.
b) Nature of the transaction	Price(s)      Volume(s) £14.296      2,489.892
	£14.296      3,908.186
c) Price(s) and volume(s)	£14.296      3,224.047
	£14.296      3,852.243
d) Aggregated information	
Aggregated volume	13,474.367
Price	£14.296
e) Date of the transaction	2018-04-12
f) Place of the transaction	London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')	
a) Name	Mr N Hirons
b) Position/status	SVP, Global Ethics & Compliance
c) Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

shareholders on 12 April  
2018 on Ordinary Shares held  
in the Company's  
Performance Share Plan.

Price(s)	Volume(s)
£14.296	876.631

c) Price(s) and volume(s)	£14.296	748.274
	£14.296	1,036.207

d) Aggregated information	2,661.111
Aggregated volume Price	£14.296

e) Date of the transaction	2018-04-12
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr D S Redfern
b) Position/status	Chief Strategy Officer
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ( 'Ordinary Shares' ) ISIN: GB0009252882
--	---

b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.
------------------------------	--

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£14.296	1,540.732
	£14.296	1,453.809
	£14.296	1,915.390

Aggregated information

- d) Aggregated volume Price 4,909.931  
£14.296
- e) Date of the transaction 2018-04-12
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms C Thomas
- b) Position/status SVP, HR
- c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.

- |                           | Price(s) | Volume(s) |
|---------------------------|----------|-----------|
| b)                        | £14.296  | 1,939.201 |
| c) Price(s) and volume(s) | £14.296  | 1,603.457 |
|                           | £14.296  | 2,171.486 |

Aggregated information

- d) Aggregated volume Price 5,714.144  
£14.296
- e) Date of the transaction 2018-04-12
- f) Place of the transaction London Stock Exchange (XLON)



1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr P C Thomson
- b) Position/status President, Global Affairs  
Initial
- c) notification/ Initial notification  
amendment

Details of the issuer, emission allowance

2. market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)

3. each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.

Price(s)	Volume(s)
£14.296	1,115.711

- c) Price(s) and volume(s)
 

£14.296	1,004.831
£14.296	1,365.746

- d) Aggregated information
 

3,486.288
Aggregated volume Price
£14.296

- e) Date of the transaction 2018-04-12
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mrs V A Whyte
  - b) Position/status Company Secretary
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£14.296	212.997
£14.296	199.988
£14.296	189.843
  - d) Aggregated information
 

Aggregated volume	602.829
Price	£14.296
  - e) Date of the transaction 2018-04-12
  - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr B McNamara
  - b) Position/status CEO, GSK Consumer Healthcare
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793  
 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument American Depository Shares ('ADSs')  
 ISIN: US37733W1053

b) Nature of the transaction Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 April 2018 on ADSs held in the Company's Performance Share Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	\$40.62	866.909
	\$40.62	1,399.614
	\$40.62	1,727.388

d) Aggregated information  
 Aggregated volume Price 3,993.911  
 \$40.62

e) Date of the transaction 2018-04-12  
 f) Place of the transaction New York Stock Exchange (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D E Troy  
 b) Position/status SVP & General Counsel  
 c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument American Depository Shares ('ADSs')  
 ISIN: US37733W1053

b) Nature of the transaction Increase in notional interest in ADSs following the re-investment of dividends

paid to shareholders on 12 April 2018 on ADSs held in the Company's Performance Share Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	\$40.62	1,775.668
	\$40.62	1,559.572

d) Aggregated information	3,335.240
Aggregated volume Price	\$40.62

e) Date of the transaction	2018-04-12
f) Place of the transaction	New York Stock Exchange (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr H Barron
b) Position/status	Chief Scientific Officer and President, R&D
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
--	---

b) Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 April 2018 on ADSs held in the Company's Performance Share Plan.
------------------------------	--

	Price(s)	Volume(s)
c) Price(s) and volume(s)	\$40.62	3,711.539
Aggregated information	n/a (single transaction)	

d) Aggregated volume Price	
e) Date of the transaction	2018-04-12

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- f) Place of the transaction New York Stock Exchange  
(XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Ms K Terrell
- b) Position/status Chief Digital & Technology  
Officer
- c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction  
platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of  
instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
place where transaction(s) has been conducted
- a) Description of the financial instrument American Depositary Shares  
(‘ADSs’)  
ISIN: US37733W1053
- b) Nature of the transaction Increase in notional interest  
in ADSs following the  
re-investment of dividends  
paid to shareholders on 12  
April 2018 on ADSs held in  
the Company's Performance  
Share Plan.
- c) Price(s) and volume(s) Price(s) Volume(s)  
\$40.62 1,432.209
- d) Aggregated information n/a (single transaction)
- e) Aggregated volume Price
- e) Date of the transaction 2018-04-12
- f) Place of the transaction New York Stock Exchange  
(XNYS)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: April 17, 2018

By: VICTORIA WHYTE

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc